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Conservative treatment in patients with 
muscle-invasive bladder cancer by transure-
thral resection, neoadjuvant chemotherapy 
with gemcitabine and cisplatin, and acceler-
ated radiotherapy with concomitant boost 
plus concurrent cisplatin – assessment of re-
sponse and toxicity.
Jadwiga NOWAK-SADZIKOWSKA, Teresa KOWALSKA, 
Jerzy JAKUBOWICZ, Teresa SZPYTMA
SUMMARY
BACKGROUND : Curative treatment options for invasive bladder cancer include radical cystectomy and 
therapeutic strategies with bladder preservation. 
AIM: To evaluate the toxicity and clinical effectiveness of transurethral resection, neoadjuvant chemo-
therapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus 
concurrent cisplatin in muscle invasive bladder cancer.
MATERIALS AND METHODS: Between October 2005 and March 2008, 27 patients with histologically 
proven invasive carcinoma of the bladder (T2-4a,N0-1,M0) who were fi t for combined radiochemo-
therapy and refused radical surgery were selected to bladder-sparing protocol.
RESULTS: In this study, a group of twenty one patients (78%) received two cycles of chemotherapy, and 
six of them (22%) only one, because of treatment related toxicity. Complete response after fi nished 
conservative treatment: transurethral resection, neoadjuvant chemotherapy with gemcytabin and cis-
platin, and accelerated hyperfractionated radiotherapy with concomitant boost plus concurrent cis-
platin, occurred in 18 patients (67%), partial response in 2 (8%), stable disease in 7(25%). Toxicities for 
hematologic and nonhematologic parameters during neoadjuvant chemotherapy were acceptable.
CONCLUSION: Conservative treatment in patients with muscle-invasive bladder cancer provides a high 
probability of local response with acceptable toxicity in properly selected patients.
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INTRODUCTION
Bladder carcinoma is the second most com-
mon malignant neoplasm of the genitourinary 
tract. In Poland, bladder cancer is the fourth 
site of incidence for males, accounting for 
about 6.5% of all cancer cases, while in fe-
males it accounts for 1.7 % [1]. It is estimated 
that about a third are muscle invasive.
Curative treatment options for invasive 
bladder cancer include radical cystectomy 
and therapeutic strategies with bladder pres-
ervation. The standard of care treatment for 
muscle-invasive bladder cancer is radical 
cystectomy, despite encouraging results of 
organ preserving regimens [2, 3]. Retrospec-
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tive review of literature indicated that radical 
surgery seems to be more effective. However, 
it should be pointed out that patients selected 
to conservative approach were in worse per-
formance status, relatively older, with more 
advanced clinical stage and with signifi cant 
comorbidites, compared with those treated by 
surgery or those who refused radical cystec-
tomy. No randomised trial has ever been per-
formed to directly compare the two treatment 
approaches. Therefore, assessment of results 
of conservative therapy in invasive bladder 
cancer could be done only by comparison 
with the results of surgery in non randomised 
study, in historical group or with results from 
different institutions.
The most optimal organ preservation ap-
proach consists of trimodality therapy, includ-
ing transurethral resection of bladder cancer 
– TURB, radiation therapy – RT and systemic 
chemotherapy CT, with cystectomy reserved 
for salvage. Numerous studies using bladder 
preserving treatment, have reported survival 
comparable to cystectomy series [4–14]. Five-
year overall survival rates in the range of 
50%–63% have been presented and approxi-
mately 75% of surviving patients maintained 
their bladder. However, the optimal manage-
ment of delivering chemotherapy and radia-
tion therapy, sequentially or concurrently, re-
mains to be determined.
Conservative local treatment: transurethral 
resection and radiotherapy in invasive blad-
der cancer patients allows to obtain fi ve-year 
overall survival within the 20%–40% range 
[15–19]. Many studies have been conducted to 
improve the results of radiotherapy in treat-
ment invasive of bladder cancer by escalation 
of total dose, adoption of altered fractionation, 
reduction in overall treatment time, combin-
ing teleradiotherapy with brachytherapy or 
using radiosensitizers [20–25]. 
Low local control and high rate of distant 
metastases caused systemic chemotherapy to 
be incorporated into local treatment of inva-
sive bladder cancer. 
We designed a protocol of transurethral re-
section, neoadjuvant chemotherapy with gem-
cytabine and cisplatin, and accelerated hyper-
fractionated radiotherapy with concomitant 
boost plus concurrent cisplatin, in an effort to 
improve both local and distant control.
AIM
Evaluation of the toxicity and clinical effec-
tiveness of transurethral resection, neoad-
juvant chemotherapy with gemcitabine and 
cisplatin, and accelerated radiotherapy with 
concomitant boost plus concurrent cisplatin 
in muscle invasive bladder cancer.
MATERIALS AND METHODS
Between October 2005 and March 2008, 27 pa-
tients with histologically proven invasive car-
cinoma of the bladder (T2-4a,N0-1,M0) who 
were fi t for combined radiochemotherapy and 
refused radical surgery were selected to blad-
der-sparing protocol. Exclusion criteria were 
as follows: Karnofsky status <70%, haemoglo-
bin < 10 g/dL, white blood cell count < 4000/
mL, platelet count <100,000/mL, serum biliru-
bin and serum creatinine level above the upper 
limit of normal, previous radiotherapy to the 
pelvis. Prior to therapy, all patients underwent 
physical examination with DRE, haematologi-
cal, renal and biochemical blood tests, CT scan 
of abdomen and pelvis, chest X-ray. Patient and 
tumour characteristics are listed in Table 1. 
Patients underwent standard transurethral 
resection of bladder tumour (TURB), and a 
complete TURB was attempted, if possible. 
Neoadjuvant chemotherapy, two cycles with 
gemcytabine and cisplatin, was started a few 
weeks after TURB. Patients received gemcit-
abine 1,000 mg/m2 over 30 to 60minutes on 
days 1, 8, and 15, plus cisplatin 70 mg/m2 on 
day 2. Cycles were repeated every 28 days. 
External beam  RT with computed tomog-
raphy-based images was performed with 6 
MV or 18 MV photon beams from linear ac-
celelator. Radiotherapy was started about 4–6 
weeks after adjuvant chemotherapy. The ir-
radiation dose per fraction was 1.8 Gy daily, 
to a total of 45Gy to the whole bladder and 
tumour with 2 cm margin, for 5 weeks – 25 
x 1.8 Gy, once daily, 5 days a week. Addition-
ally, all patients received a concomitant boost 
to the whole bladder and tumour with 1.5 cm 
margin, during the two last weeks of treat-
ment, as a second fraction to the total dose of 
60 Gy. A four-fi eld technique was used with 
individually shaped portals by multi-leaf col-
limators (MLC). Patients were treated with 
empty bladder, and a 6 hour interval between 
two fractions a day was mandatory. 
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Concurrent chemotherapy was applied in 
days 1, 2, 15, 16, 29, 30 of radiotherapy and 
consisted of cisplatin – 20mg/m2 in 30 min 
infusion, 3-4 hours before irradiation. Acute 
toxicities were recorded every week accord-
ing to the National Cancer Institute Common 
Toxicity Criteria and RTOG/EORTC Radia-
tion Morbidity Scoring Criteria [26]
Initial treatment response was assessed 
4–6 weeks after neoadjuvant chemotherapy, 
by re-eveluation of tumour size by computed 
tomography of pelvis.
Six to eight weeks after completion of RCT, 
response was evaluated by control cystoscopy 
with biopsy of the former tumour region or 
TURB. In case of histologically proven com-
plete response, patients were followed up at 
3-month intervals for the fi rst 3 years and 
every 6 months thereafter. Evaluations con-
sisted of physical examination and cystoscopy 
with biopsies of suspected areas. Each year, 
abdominopelvic computed tomography, chest 
X-ray or other instrumental examinations, if 
indicated, were performed. For persistent or 
recurrent invasive tumour, salvage cystecto-
my was recommended. 
RESULTS
In this study, a group of twenty one patients 
(78%) received two cycles of chemotherapy, 
and six of them (22%) only one, because of 
treatment related toxicity. In one patient, ad-
juvant chemotherapy was discontinued after 
fi rst cycle, due to severe acute toxicity – leu-
copenia G4, neutropenia G4, gastrointestinal 
toxicity G4. Modifi cation of doses, delay or 
omission in administration of cytotatics were 
reported in 16 patients (60%). Granulocytic 
colony-stimulating factors were used in 8 pa-
tients (30%) to preserve the regime of chemo-
therapy.
Ten patients (37%) in this group received 
chemotherapy consisting of gemcytabine with 
carboplatin instead of gemcitabine and cispla-
tin, due to abnormal renal function and/or se-
vere heart disease. 
Only as few as 9 patients (33%) received 
combined irradiation with cisplatin. The re-
maining patients were not treated with cispla-
tin during irradiation, due to exacerbation of 
chronic comorbid disease. 
The combined therapy – neodajuvant che-
motherapy followed by radiotherapy with low 
doses of cisplatin or only radiotherapy, were 
generally well tolerated. 
Toxicities for hematologic and nonhemato-
logic parameters during neoadjuvant chemo-
therapy are provided in Table 2. 
All patients completed their planned course 
of radiation therapy. There were no complica-
tions worse than grade 2 in this group, during 
irradiation. The rates of grade 1–2 acute geni-
tourinary and gastrointestinal complications 
are shown in Table 3.
Initial treatment response, after neoadju-
vant chemotherapy, assessed in all patients 
presented complete response in 8 patients 
(30%), partial response in 13 (48%), stable dis-
ease in 6 (22%). 
Complete response after fi nished conserva-
tive treatment: transurethral resection, neo-
adjuvant chemotherapy with gemcytabin and 
cisplatin, and accelerated radiotherapy with 
concomitant boost plus concurrent cisplatin, 
Table 1. Characteristics of 27 patients with invasive bladder 
cancer
Characteristics Number of patients (%)
Age
mean
range
64
47-76
Karnofsky status
70
80
90
17(63%)
9 (33%)
1 (4%)
Gender
male
female
23 (85%)
4 (15%)
T stage
T2
T3
T4
6 (22%)
13 (48%)
8 (30%)
N stage 
No
N1
26 (96%)
1 (4%)
Histological grade
G1
G2
G3
–
8 (30%)
19 (70%)
Ureter obstruction 
Yes
No
5 (18%)
22 (82%)
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occurred in 18 patients (67%), partial response 
in 2 (8%), stable disease in 7(25%). 
In a group of patients with persistent dis-
ease, 6 were unfi t for surgery due to stage of 
disease or/and performance status, one un-
derwent salvage cystectomy, two consider 
submission to salvage cystectomy. 
At the time of analysis, the median follow-
up time for all patients was 18 months (range 
from 5 to 41 months). Further observation al-
lows to asses overall survival and disease spe-
cifi c survival, percentage of preserved blad-
der and late toxicity.
DISCUSSION 
The standard of care treatment for muscle-
invasive bladder cancer is radical cystecto-
my. However, various of studies have inves-
tigated the effi cacy and toxicity of combined 
bladder sparing approach in invasive blad-
der cancer, generally with encouraging ef-
fects [4–14, 27–30]. TURB, followed by ra-
diotherapy combined with chemotherapy, 
becoming the most appropriate scheme of 
organ preservation treatment in bladder in-
vasive cancer. 
Cisplatin counts among the most effective 
cytoststatic agents used in monotherapy in 
chemotherapy of invasive bladder cancer [31, 
32]. Randomised trial, conducted by Saxman 
et al, has demonstrated that MVAC (metho-
trexate, vinblastyne, doxorubicin, and cis-
platin) regimen, in terms of overall survival, 
is superior to cisplatin alone [32]. Cisplatin 
based combination chemotherapy regimens, 
like MVAC or CMV (cisplatin, methotrexate, 
and vinblastine), are established current stan-
dard treatments for metastastatic urotherial 
carcinoma. Although cisplatin based regimens 
produce high tumour responses, the long-
term, disease-free survival rate is only 3.7% 
at 6 years. Furthermore, the toxicity of these 
regimens is considerable, MVAC is associated 
with toxic death rate of 3% to 4%. In search 
of improvement in toxicity profi le, new regi-
mens are investigated. In randomised trial, 
GC (Gemcitanine, Cisplatin) provided results 
similar to MVAC, with better safety profi le 
and tolerability [33]. This better-risk benefi t 
ratio changes the standard of care for patients 
with locally advanced and metastatic transi-
tional cell carcinoma from MVAC to GC. 
Despite many randomized controlled tri-
als carried out, controversy still exists as to 
whether  neoadjuvant chemotherapy improves 
survival in patients with invasive bladder can-
cer [34–37]. Meta-analysis assessed effect of 
neoadjuvant combination, platinum-based che-
motherapy in treatment of invasive bladder 
cancer showed a signifi cant benefi t to overall 
survival which increased from 45% to 50%, 
and reduced the risk of death by 13% [38]. This 
effect was observed irrespective of the type 
of local treatment. However, the results of the 
randomized trial (RTOG 89-03) comparing two 
treatment arms of RT and concurrent cisplatin 
with or without neodjuvant chemotherapy, us-
ing MCV scheme, reported no differences in 
terms of local control, survival without metas-
tases and overall survival [39]. The presented 
data suggested that prolongation of treatment 
time could have unfavourable effect. 
In our series, 21 patients (78%) competed 
two planned cycles of neodjuvant chemo-
therapy with gemcytabin and cisplatin with 
Table 2. Acute toxicity during neoadjuvant chemotherapy in a group of 27 patients with invasive bladder cancer
Acute toxicity grade Anaemia Leucopenia Neutropenia Thrombocytopenia Gastrointestinal
G1 3 (11%) 10 (37%) 7 (26%) 1 (4%) –
G2 2 (8%) 7 (26%) – 3 (11%) –
G3 – – 6 (22%) 6 (22%) –
G4 – 1 (4%) 1 (4%) 1 (4%) 1 (4%)
Table 3. Acute toxicity during irradiation in a 
group of 27 patients with invasive bladder cancer
Acute toxicity 
grade Gastrointestinal Genitourinary
G1 12 (44%) 9 (33%)
G2 4 (15) 12 (44%)
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minor or no deviations. Grade 4 toxicity re-
lated to chemotherapy was observed in 2 (8%) 
patients, grade 3 in 12 (44%) patients during 
neoadjuvant chemotherapy what is similar to 
privious data [34–37].  
Clinical research on using cisplatin in com-
bination with RT, in patients with invasive 
bladder cancer has demonstrated objective 
tumour responses coming up to 80%, with ac-
ceptable toxicity [7–8, 10–11, 27, 40–41]. The 
only randomized comparison of RT versus 
RT with cisplatin in advanced bladder cancer, 
showed an improved local control without in-
fl uence on overall survival [40]. 
Using lower radiosensitizing dose of cispla-
tin in treatment of head and neck carcinoma, 
improved outcome, with decrease of toxic-
ity in comparison with high dose of Cisplatin 
given in cycles [42–43]. Using daily low dose 
of cisplatin (6mg/m2) with accelerated radio-
therapy, in patients with invasive bladder can-
cer, in a prospective study, was feasible with 
acceptable tolerance, even in relatively old 
patients [41]. 
With only 9 patients (33%) who received 
combined chemoradiotherapy with cisplatin 
after neodjuvant chemotherapy consisting of 
gemcitabine with cisplatin, this regimen ap-
pears to be poorly tolerated by most patients. 
TURB followed by chemoradiotherapy seems 
to be more appropriate scheme of treatment 
allowing to reduce overall treatment time, 
decrease toxicity prolong neodjuvant chemo-
therapy and eliminate progression during in-
duction.  
The goals of irradiation include eradication 
of local tumour, maintenance of normal organ 
function and preservation of good quality of 
life. 
Although the survivals for conventional 
RT are as good as those seen for cystectomy, 
with overall 5-year survival rate of 24–40% 
and a bladder cancer- specifi c survival rate of 
31–56,8% (in all stages), there is still need for 
improved local control [15–19]. 
The main failure of conventional radical 
radiotherapy for invasive bladder cancer is 
local incurrence or recurrence observed in 
one-half of patients within the time of one to 
two years, which indicates fast proliferation 
of tumour cells [7, 15, 16]. According to the 
retrospective analysis by Maciejewski and 
Majewski, potential doubling time of tran-
sitional cell carcinoma is 5–8 days, and the 
acceleration of the clonogenic repopulation of 
tumours becomes evident in 5–6 weeks after 
start of conventional radiotherapy [44]. Also 
assessment of cell kinetics by bromodeoxyu-
ridine index has shown high proliferative 
activity and short potential doubling times, 
3–8 days, of muscule invasive bladder cancer 
[45–46].
Looking for a way to eliminate this unfa-
vourable effect, reduction of the overall treat-
ment time by altered fractionation has been 
investigated in an attempt to improve local 
control. However, this cannot be achieved by 
an increase in the dose per fraction due to 
high risk of severe toxicity. Normal bladder 
and bowel tissues are known to be sensitive to 
large fraction size. Results of published ran-
domised phase III trial comparing acceler-
ated fractionation with conventional fraction, 
showed no improvement of the accelerated 
arm [47]. 
Therefore, multiple fractions per day are 
necessary if the required bladder tumour dose 
is to be delivered in a shorter time. 
On the other hand, some authors consider 
that the effect of the overall treatment time 
(OTT) in invasive bladder cancer is diffi cult to 
defi ne [48, 49] or they even did not fi nd a sta-
tistically signifi cant correlation between local 
control and treatment time [50].  
One of the methods of altered fractionation, 
used in treatment of invasive bladder cancer, 
is accelerated superfractionated radiotherapy 
with concominatnt boost which allows to ob-
tain complete response RC in about 74–80% of 
invasive bladder carcinoma patients, with ac-
ceptable toxicity [8, 22–23]. 
In our series there was observed CR rate 
– 67%, what is similar to that in other blad-
der sparing regimens. However, it should be 
noted that majority of treated patients were 
in advanced stage of disease – 70% of patients 
treated with T3-T4. 
Acute bowel toxicity and acute urinary tox-
icity during accelerated hiperfractionated ra-
diotherapy with concominatnt boost for inva-
sive bladder cancer, were observed in 74–95% 
and 74–91 of the patients, respectively, what is 
consistent with our observations [8, 22–23]. We 
observed acute bowel and urinary toxicity, no 
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worse than grade 2, in 59% and 77%, respec-
tively. All patients received planed irradiation 
with prescribed dose, on schedule time.
Severe late bowel and urinary toxicities 
were reported in 0–7% and 2–10% of the pa-
tients, respectively, and they are comparable 
with toxicity of conventional radiotherapy [8, 
22–23].
Another strategy is to target tumour cell 
repopulation by the addition of chemotherapy 
[7–8, 10–11, 27, 41–42]. Rapid proliferation 
is associated with improved local control, 
if patients are treated with concurrent ra-
diochemotherapy [51]. The cytotoxic effect of 
concurrent chemotherapy may effectively in-
hibit repopulation during fractionated radio-
therapy. 
Toxicity is caused also by delivering high 
dose of radiation to the entire pelvis. The role 
of prophylactic irradiation of clinically un-
involved pelvic lymph for invasive bladder 
cancer, has not been completely elucidated 
[52–54]. Retrospective comparisons of out-
come with radiation fi elds including pelvic 
lymph nodes versus treatment of bladder only, 
show confl icting results. Reduction in irradi-
ated fi elds to bladder and tumour with a mar-
gin, allows to limit healthy tissue irradiated 
with high dose and, in consequence, should 
reduce the toxicity of treatment. Moreover, 
combination of irradiation limited to the blad-
der and tumour with a margin, with systemic 
chemotherapy, has at least additive effect on 
reducing treatment failure caused by regional 
lymph node involvement. In our protocol, the 
treated volume was reduced to bladder and tu-
mour with margin.
Also severity and incidence of late toxicity 
is closely related to the proportion of organ ir-
radiated, with the radiation tolerance of a part 
of bladder grater that of the organ as a whole. 
In randomised trial, reduction in treatment 
volume to the tumour-bearing region of the 
bladder, allowed delivery of an increased ra-
diation dose without reduction in local tumour 
control or development of excessive toxicity 
[55]. 
The standard radiotherapy regiment for 
invasive bladder cancer is irradiation of the 
whole bladder and tumour with 2–3 cm mar-
gin to a dose of 60–66 Gy with conventional 
fractionation [16]. Due to limited tolerance of 
the normal bladder cancer and surrounding 
normal tissue, the total dose used in treat-
ment of invasive bladder cancer is relatively 
low compare with doses used in other solid 
tumours. Some authors report the importance 
of total dose on outcome for bladder cancer. 
Pos et al showed a signifi cant decrease in 
local control of bladder cancer treated with 
high-dose-rate brachytherapy  when com-
pared with low-dose rate-brachyterapy, sug-
gesting a dose-response relationship for inva-
sive bladder cancer [25].
 
CONCLUSION 
Conservative treatment in patients with mus-
cle-invasive bladder cancer by transurethral 
resection, neoadjuvant chemotherapy with 
gemcytabin and cisplatin, and accelerated hy-
perfractionated radiotherapy with concomi-
tant boost plus concurrent cisplatin provides a 
high probability of local response with accept-
able toxicity in properly selected patients. 
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